The use of clobazam, midazolam, and nitrazepam in epilepsy

Epilepsia

Volumn 39, Issue SUPPL. 1, 1998, Pages

  Shorvon, Simon D ^a,b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c EPILEPSY SOCIETY   (United Kingdom)

Author keywords

Antiepileptic drugs; Benzodiazepines; Clobazam; Midazolam; Nitrazepam; Side effect profile

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CLOBAZAM; MIDAZOLAM; NITRAZEPAM;

APNEA; ATAXIA; CONFERENCE PAPER; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG USE; EPILEPSY; EPILEPTIC STATE; EUROPE; FATIGUE; FOCAL EPILEPSY; GRAND MAL SEIZURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE HYPOTONIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; RESPIRATORY ARREST; VERTIGO;

EID: 0031931727     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb05109.x     Document Type: Conference Paper

References (80)

1. Shorvon S. Benzodiazepines: clobazam. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:763-77.
2. Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol 1979;7(suppl 1);51S-7S.
3. Aucamp AK. Aspects of the pharmacokinetics and pharmacodynamics of benzodiazepines with particular reference to clobazam. Drug Dev Res Suppl 1982;1:117-26.
4. Volz M, Christ O, Kellner H-M, et al. Kinetics and metabolism of clobazam in animals and man. Br J Clin Pharmacol 1979;7(suppl 1):41S-50S.
5. Jawad S, Oxley J, Wilson J, Richens A. A pharmacodynamic evaluation of midazolam as an antiepileptic compound. J Neurol Neurosurg Psychiatry 1986;49:1050-4.
6. Wolf P. Clobazam in drug-resistant patients with complex focal seizures - report of an open study. In: Hindmarch I, Stonier PD, Trimble MR, eds. Clobazam: human psychopharmacology and clinical applications. International congress and symposium series, no. 74. London: Royal Society of Medicine, 1985:167-71.
7. Gastaut H, Low M. Antiepileptic properties of clobazam, a 1,5 benzodiazepine in man. Epilepsia 1979;20:437-66.
8. Critchley EMR, Valil SD, Hayward HW, Owen MVH, Cocks A, Freemantle NP. Double-blind clinical trial of clobazam in refractory epilepsy. In: Hindmarch I, Stonier PD, eds. Clobazam. International congress and symposium series, no. 43. London: Royal Society of Medicine, 1981:159-63.
9. Feely M, Calvert R, Gibson J. Clobazam in catamenial epilepsy. A model for evaluating anticonvulsants. Lancet 1982;2:71-3.
10. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: avoid tolerance. J Neurol Neurosurg Psychiatry 1984;47:1279-82.
11. Allen J, Oxley J, Robertson M, Richens A, Jawad S. Clobazam as adjunctive treatment in refractory epilepsy. BMJ 1983;286:1246-7.
12. Dellaportas CI, Wilson A, Clifford RF. Clobazam as adjunctive treatment in chronic epilepsy. In: Porter RJ, Mattson RH, Ward AA Jr, Dam M, eds. Advances in epileptology: XVth Epilepsy International Symposium. New York: Raven Press, 1984:363-7.
13. Wilson A, Dellaportas CI, Clifford RF. Low-dose clobazam as adjunctive therapy in chronic epilepsy. In: Hindmarch I, Stonier PD, Trimble MR, eds. Clobazam: human psychopharmacology and clinical applications. International congress and symposium series, no. 74. London: Royal Socity of Medicine, 1985:172-8.
14. Schmidt D, Rhode M, Wolf P, Roeder-Warner U. Tolerance to the antiepileptic effect of clobazam. In: Frey H-H, Froscher W, Koella WP, Meinardi H, eds. Tolerance to beneficial and adverse effects of antiepileptic drugs. New York: Raven Press, 1986:109-18.
15. Koeppen D, Baruzzi A, Capozza M, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind, placebo-controlled, crossover study. Epilepsia 1987;28:495-506.
16. Keene DL, Whiting S, Humphrey P, Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990;17:317-9.
17. Dulac O, Figueroa D, Rey E, Arthuis M. Monothérapie par le clobazam dans les épilepsies de l'enfant. Presse Médicale 1983; 12:1067-9.
18. Plouin P, Jalin C. EEG changes in epileptic children treated with clobazam as monotherapy. In: Hindmarch I, Stonier PD, Trimble MR, eds. Clobazam: human psychopharmacology and clinical applications. International congress and symposium series, no. 74. London: Royal Society of Medicine, 1985:101-7.
19. Canadian Clobazam Cooperative Study. Clobazam in the treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 1991;32:407-16.
20. Gastaut H. The effects of benzodiazepines on chronic epilepsy in man (with particular reference to clobazam). In: Hindmarch I, Stonier PD, eds. Clobazam. International congress and symposium series, no. 43. London: Royal Society of Medicine, 1981:141-50.
21. Bianchi A, Bollea A, Sider G. Lemploi du clobazam dans l'épilepsie; experience d'un an de traitement. In: Canger R, Avanzini G, Tassinari CA, eds. Progressi in epilettologia. Boll Lexa Italiana Contra l'Epilepsia 1980;29-30:215-8.
22. Oxley J. Tolerance to the antiepileptic effect of clobazam in patients with severe epilepsy. In: Frey H-H, Froscher W, Koella WP, Meinardi H, eds. Tolerance to beneficial and adverse effects of antiepileptic drugs. New York: Raven Press, 1986.
23. Koeppen D. A review of clobazam studies in epilepsy. In: Hindmarch I, Stonier PD, Trimble MR, eds. Clobazam: human psychopharmacology and clinical applications. International congress and symposium series, no. 74. London: Royal Society of Medicine, 1985;207-15.
24. Robertson MM. Current status of the 1,4 and 1,5 benzodiazepines in the treatment of epilepsy: the place of clobazam. Epilepsia 1986; 27(suppl 1):S27-41.
25. Koeppen D. Clinical experience with clobazam (1968-1981). In: Hindmarch I, Stonier PD, eds. Clobazam. International congress and symposium series, no. 43. London: Royal Society of Medicine, 1981:193-8.
26. Dundee JW, Halliday NJ, Harper KW, Brogden RN. Midazolam: a review of its pharmacological properties and therapeutic use. Drugs 1984;28:519-43.
27. Brown CR, Sarnquist FH, Canup CA, Pedley TA. Clinical electroencephalographic and pharmacokinetic studies of a water-soluble benzodiazepine, midazolam maleate. Anaesthesiology 1979;50:467-70.
28. Raines A, Henderson TR, Swinyard EA, Dretchen KL. Comparison of midazolam and diazepam by the intramuscular route for the control of seizures in a mouse model of status epilepticus. Epilepsia 1990;31:313-7.
29. Kubova H, Mares P. The effect of ontogenetic development on the anticonvulsant activity of midazolam. Life Sci 1992;50:1665-72.
30. Jaimovich DG, Shabino CL, Noorani A, Bittle BK, Osborne JS. Intravenous midazolam suppression of pentylenetetrazol-induced epileptogenic activity in a porcine model. Crit Care Med 1990;18: 313-6.
31. Larsen F, Clausen TG, Wolff J, Hansen P, Rasmussen SN. Absorption profiles of rectally administered midazolam estimated by deconvolution. Eur J Drug Metab Pharmacokinet 1991;3:291-6.
32. Patsalos PN, Bell DM, Richards G, et al. Pharmacokinetic evaluation of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsia 1991;32(suppl 1):S29.
33. Bell DM, Richards G, Dhillon S, et al. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Res 1991;10:183-90.
34. Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:1693.
35. Breimer LT, Burm AG, Danhof M, et al. Pharmacokinetic-pharmacodynamic modelling of the interaction between flumazenil and midazolam in volunteers by aperiodic EEG analysis. Clin Pharmacokinet 1991;20:497-508.
36. Koopmans R, Dingmanse J, Danhof M, Horsten GP, van Boxte CJ. The influence of dosage time of midazolam on its pharmacokinetics and effects in humans. Clin Pharmacol Ther 1991;50:16-24.
37. Driessen JJ, Vree TB, Guelen PJ. The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients. Acta Anaesthesiol Belg 1991;42: 149-55.
38. Ghilain S, Van Rijckevorsel-Harmant K, Harmant J, De Barsy TH. Midazolam in the treatment of epileptic seizures. J Neurol Neurosurg Psychiatry 1988;51:732.
39. Kaneko S, Kurahashi K, Fujita S, Fukushima Y, Sato T, Hill RG. Potentiation of GABA by midazolam and its therapeutic effect against status epilepticus. Folia Psychiatr Neurol Jpn 1983;37: 307-9.
40. Galvin GM, Jelinek GA. Midazolam: an effective intravenous agent for seizure control. Arch Emerg Med 1987;4:169-72.
41. Crisp CB, Gannon R, Knauft F. Continuous infusion of midazolam hydrochloride to control status epilepticus. Clin Pharmacol 1988; 7:322-4.
42. Mayhue FE. IM midazolam for status epilepticus in the emergency department. Ann Emerg Med 1988;17:643-5.
43. Lahat E, Aladjem M, Eshel G, Bistritzer T, Katz Y. Midazolam in treatment of epileptic seizures. Pediatr Neurol 1992;8:215-6.
44. Rivera R, Segnini M, Baltodano A, Pérez V. Midazolam in the treatment of status epilepticus in children. Crit Care Med 1993; 21:991-4.
45. Cortina J, Ancillo P, Duarte J, Sempere AP, Coria F, Claveria LE. Intravenous midazolam suppression of complex partial status refractory to intravenous phenytoin and diazepam. Clin Neuropharmacol 1993;16:468-70.
46. Shorvon SD. Status epilepticus: its clinical features and treatment in children and adults. Cambridge: Cambridge University Press, 1994:233.
47. Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 1992;20:483-8.
48. Egli M, Albani C. Relief of status epilepticus after IM administration of the new short-acting benzodiazepine midazolam (Dormicum). Excerpta Medica, ICS 1981;44:548.
49. Wroblewski BA, Joseph AB. The use of intramuscular midazolam for acute seizure cessation of behavioral emergencies in patients with traumatic brain injury. Clin Neuropharmacol 1992;15:44-9.
50. Baruzzi A, Michelucci R, Tassinari CA. Nitrazepam. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995;735-49.
51. Jochemsen R, Hogendoorn JJH, Dingemanse J, Hermans J, Boeijinga JK, Breimer DD. Pharmacokinetics and bioavailability of intravenous, oral and rectal nitrazepam in humans. J Pharmacokinet Biopharm 1982;10:231-45.
52. Rieder J, Wendt G. Pharmacokinetics and metabolism of the hypnotic nitrazepam. In: Garattini S, Mussini E, Randall L, eds. The benzodiazepines. New York: Raven Press, 1973:99-127.
53. Jochemsen R, Van der Graaff M, Boeijinga JK, Breimer DD. Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. Br J Clin Pharmacol 1982;13:319-24.
54. Abernethy DR, Greenblatt DJ, Locniskar A, Ochs HR, Harmatz JS, Shader RI. Obesity effects on nitrazepam disposition. Br J Clin Pharmacol 1986;22:551-7.
55. Greenblatt DJ, Abernethy DR, Locniskar A, Ochs HR, Harmatz JS, Shader RI. Age, sex and nitrazepam kinetics: relation to antipyrine disposition. Clin Pharmacol Ther 1985;38:697-703.
56. Rieder J. Plasma levels and derived pharmacokinetic characteristics of unchanged nitrazepam in man. Arzneimittelforschung 1973; 23:212-8.
57. Kangas L, Breimer DD. Clinical pharmacokinetics of nitrazepam. Clin Pharmacokinet 1981;6:346-66.
58. Kangas L, Lisalo E, Kanto J, et al. Human pharmacokinetics of nitrazepam: effect of age and diseases. Eur J Clin Pharmacol 1979;15:163-70.
59. Browne TR, Penry JK. Benzodiazepines in the treatment of epilepsy. Epilepsia 1973;14:277-310.
60. Greenblatt DJ, Allen MD. Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol 1978;5:407-13.
61. Hagberg B. The Librium-analogue Mogadon in the treatment of epilepsy in children. Acta Neurol Scand 1967;31:167.
62. Jan JE, Riegl JA. Nitrazepam in the treatment of convulsive disorders. Clin Res 1970;18:220.
63. Wyllie E, Wyllie R, Cruse RP, Rothner AD, Eremberg G. The mechanism of nitrazepam-induced drooling and aspiration. N Engl J Med 1986;314:35-8.
64. Girdwood RH. Nitrazepam nightmares. BMJ 1973;1:353.
65. Gibbs FA, Anderson EM. Treatment of hypsarrhythmia and infantile spasms with a Librium analogue. Neurology 1965;15:1173-6.
66. Peterson WG. Clinical study of Mogadon, a new anticonvulsant. Neurology 1967;17:878-80.
67. Lim HCN, Nigro MA, Beirwaltes P, Tolia V, Wishnow R. Nitrazepam-induced cricopharyngeal dysphagia, abnormal esophageal peristalsis and associated bronchospasm: probable cause of nitrazepam related sudden death. Brain Dev 1992;14:309-14.
68. Murphy JV, Sawasky F, Marquardt KM, Harris DJ. Deaths in young children receiving nitrazepam. J Pediatr 1987;111:145-7.
69. Darcy L. Delirium tremens following withdrawal of nitrazepam. Med J Aust 1972;2:450.
70. Liske E, Forster FM. Clinical study of a new benzodiazepine as an anticonvulsant agent. J N Drugs 1963;3:241-4.
71. Lacy JR, Penry JK, eds. Infantile spasms. New York: Raven Press, 1976:98-9.
72. Millichap JG, Ortiz WR. Nitrazepam in myoclonic epilepsies. Am J Dis Child 1966;112:242-8.
73. Benedetti P, Ammaniti M, Cogliati Dezza G. L'impiego del Ro4-5360 nell'epilessia infantile, contributo clinico. Infanzia Anormale (Roma) 1967;75:287-96.
74. Snyder CH. Myoclonic epilepsy in children: short-term comparative study of two benzodiazepine derivatives in treatment. South Med J 1968;61:17-20.
75. Lundberg PO, Stalberg E. Mogadon in der Behamdlung von Epilepsie bei Erwachsenen. Arch Psychiatr Nervenkr 1971;214:46-55.
76. Jeavons PM. Choice of drug therapy in epilepsy. Practitioner 1977;219:542-56.
77. Jong TH. Klinische erfahrungen mit dem Benzodiazepinderivat Ro-4 5360 bei der Behandlung der Epilepsie. Schweiz Med Wochenschr 1964;94:730-3.
78. Grossi-Bianchi ML, Pistone FM. Effetto ipnogeno ed effetto anticomiziale del nitrazepam nei bambini. Minerva Pediatr 1967;19: 1073-82.
79. Hagberg B. The chlordiazepoxide HCl (Librium) analogue nitrazepam (Mogadon) in the treatment of epilepsy in children. Dev Med Child Neurol 1968;10:302-8.
80. Vanasse M, Geoffroy G. Treatment of epilepsy with nitrazepam. In: Wada JA, Penry JK, eds. Advances in epilepsy: Xth Epilepsy International Symposium. New York: Raven Press, 1980:503.